HAS-BLED Score

The HAS-BLED Score is a validated clinical tool for assessing the risk of major bleeding in patients with atrial fibrillation who are being considered for or are already receiving anticoagulation therapy. Developed from the Euro Heart Survey on Atrial Fibrillation cohort by Pisters and colleagues in 2010, this scoring system helps clinicians balance the benefits of stroke prevention against the risks of bleeding when managing anticoagulation in AF patients.

The acronym HAS-BLED represents nine risk factors for major bleeding: Hypertension with uncontrolled systolic blood pressure above 160 mmHg (1 point), Abnormal renal function such as chronic dialysis, renal transplantation, or serum creatinine above 2.26 mg/dL (1 point), Abnormal liver function including chronic hepatic disease or biochemical evidence of significant hepatic derangement (1 point), Stroke history (1 point), Bleeding history or predisposition (1 point), Labile INR defined as unstable or high INRs or less than 60% time in therapeutic range (1 point), Elderly defined as age above 65 years (1 point), Drugs including concomitant antiplatelet agents or NSAIDs (1 point), and Alcohol excess of 8 or more drinks per week (1 point).

A HAS-BLED score of 3 or higher indicates high bleeding risk and warrants careful consideration of modifiable risk factors before and during anticoagulation therapy. Critically, a high HAS-BLED score should not be used as a reason to withhold anticoagulation in patients with a clear indication for stroke prevention. Instead, it should prompt clinicians to address modifiable bleeding risk factors such as uncontrolled hypertension, concomitant antiplatelet or NSAID use, excessive alcohol consumption, and labile INR (by switching from warfarin to a DOAC if appropriate).

The distinction between modifiable and non-modifiable bleeding risk factors is central to the clinical utility of the HAS-BLED score. Modifiable factors include uncontrolled hypertension, labile INR on warfarin, concomitant use of NSAIDs or antiplatelet agents (when not clearly indicated), and alcohol excess. Non-modifiable factors include age, history of stroke, renal or liver disease, and prior major bleeding. Addressing modifiable factors can substantially reduce bleeding risk while maintaining the stroke prevention benefits of anticoagulation.

The HAS-BLED score has been validated in multiple cohorts and is endorsed by the European Society of Cardiology in its atrial fibrillation management guidelines. It has demonstrated superior predictive ability compared to earlier bleeding risk scores including HEMORR2HAGES and ATRIA scores. The annual major bleeding rates associated with HAS-BLED scores range from approximately 1% for scores of 0-1 to over 12% for scores of 5 or higher, providing clinicians with a quantitative framework for risk communication with patients.

In clinical practice, the HAS-BLED score should be used alongside the CHA2DS2-VASc score to facilitate informed shared decision-making about anticoagulation. For most patients with CHA2DS2-VASc scores of 2 or higher, the net clinical benefit of anticoagulation exceeds the bleeding risk even when HAS-BLED is elevated. The score serves as a prompt for risk factor optimization rather than a contraindication to essential anticoagulation therapy. Regular reassessment of both stroke risk and bleeding risk is recommended as patient conditions evolve over time.